Biotechnology company Oragenics will host a management webinar on May 20, 2025, to provide insights into its innovative concussion treatment program, focusing on the lead drug candidate ONP-002. The intranasal therapy represents a potential breakthrough in addressing mild traumatic brain injury (mTBI), a significant medical challenge affecting millions annually.
The webinar will feature key leadership, including CEO Janet Huffman, Chief Medical Officer Dr. James Kelly, and Chief Clinical Officer Dr. Frank Peacock, a national emergency medicine expert. Presenters will discuss the unmet medical need in concussion treatment and share details about ONP-002's preclinical results, which demonstrate promising capabilities in reducing brain inflammation and swelling.
Currently in Phase IIa clinical trials, ONP-002 represents an important advancement in neurological therapeutic approaches. The intranasal delivery method could offer potential advantages over traditional treatment modalities, potentially providing faster and more targeted intervention for patients experiencing mild traumatic brain injuries.
The webinar offers medical professionals, researchers, and investors an opportunity to gain deeper understanding of emerging treatment strategies for concussion management. By highlighting the drug's potential, Oragenics aims to draw attention to innovative approaches in addressing neurological trauma and advancing medical understanding of brain injury treatment.
